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I. INTRODUCTION
There are places where the patent system has gone too far... [1 oo
much patent protection can in fact trample our civil liberties.
Tania Simmoncelli'
The story is becoming an all too familiar tale. What was once described as an
innovation in women's cancer research has turned into a nightmare for many of
the women it was intended to help. For the women named as plaintiffs in the
latest lawsuit against the United States Patent and Trademark Office (USPTO) and
Myriad Genetics Laboratories, Inc. (Myriad Genetics), the tale has hit especially
close to home. Each plaintiff s story is different, but the offenders, the USPTO
and Myriad Genetics, are the same. One woman, Lisbeth Ceriani, developed
breast cancer in May 2008.2 After her physician advised that she be tested for
BRCA1 and BRCA2 gene mutations to determine whether she was at an increased
risk of developing ovarian cancer, she was informed that Myriad Genetics would
not accept her insurance, MassHealth. 3 Unable to pay out-of-pocket for the
procedure, she has not been tested to date.4 As Ms. Ceriani sees it, "Myriad holds
[her] fate and future in its administrative hands."5
Another woman, Genae Girard, was also diagnosed with breast cancer and
underwent BRCA1 and BRCA2 gene testing.6 When she sought out a second
opinion upon receiving a positive result for a mutation, she was told that receiving
a second opinion would not be possible.7 Ms. Girard is now "forced to make, and
continues to make, significant medical decisions for herself based on a test result
that has not been verified by another laboratory."8 Four additional women, who
joined the lawsuit as plaintiffs, echo similar struggles to those of Ms. Ceriani and
Ms. Girard.9 The ties that bind each of these women to Myriad Genetics are the
SLiberate the Breast Cancer Genes, http://www.youtube.com/watch.v=6h6X46-qzl4 (last
visited Feb. 27, 2010).
2 Complaint at 10, Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09
Civ. 4515 (S.D.N.Y. May 12, 2009), 2009 WL 1343027.
3 Id.
4 Id.
s Donna Young, ACLU, Other Groups File Suit to Challenge BRCA Patents, BIoWORLD TODAY,
May 14, 2009, Vol. 20, Issue 92, available at 2009 WLNR 9127521.
6 Complaint, supra note 2, at 11.
7Id.
8 Id
9 Id at 10-13.
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seven United States patents that the USPTO granted Myriad Genetics on the
BRCA1 and BRCA2 genes.' °
Patents have been granted on approximately 4,382 human genes to date, which
accounts for about twenty percent of all genes in the human body." Two such
genes are BRCA1 and BRCA2, which are proven indicator genes linked to breast
and ovarian cancer.' 2 The determination that a woman has one of these mutations
allows the patient and her physician to plan ways to combat the heightened
possibility of future cancers. 3 These indicator genes have been preliminarily
linked to several other types of cancers in both men and women, as well as to
other familial genetic diseases. 4 The testing for these gene mutations is
performed through a simple blood sample taken at a physician's office.'
Individual results are then analyzed against other known mutations to determine
an individual's susceptibility. 6 Just because a woman tests positive for the
mutation does not mean that she will develop cancer, however because these
mutations tend to be hereditary, an individual's genetic testing can determine the
risk of a mutation not only in the person being tested but also in that person's
relatives.' 7
On May 12, 2009, the plaintiffs filed a lawsuit against the USPTO, Myriad
Genetics, and ten directors of the University of Utah Research Foundation (the
entity that sponsored the research). 8 The lawsuit was brought on behalf of four
professional associations, eight researchers and professors, and six current or
potential breast and ovarian cancer patients.' 9 The complaint challenges the gene
patents covering BRCA1 and BRCA2 that were granted to Myriad Genetics by the
USPTO. ° The plaintiffs claim that the patents granted unnecessarily restrict ease
of access to the genetic material needed for additional research.2' The plaintiffs
10 U.S. Patent Nos. 5,747,282 (filed June 7, 1995); 5,837,492 (filed Apr. 29, 1996); 5,693,473
(filed June 7, 1995); 5,709,999 (filed June 7, 1995); 5,710,001 (filed June 7, 1995); 5,753,441 (filed
Jan. 5, 1996); 6,033,857 (filed Mar. 20, 1998).
1 Robert S. Boyd, Human Gene Patents Can Hinder Research, Suit Says, ST. LouIs POST-DISPATCH,
June 5, 2009, at A15, available at 2009 WLNR 10819529.
12 BRCA1 and BRCA2: Cancer Risk and Genetic Testing, National Cancer Institute, http://
www.cancer.gov/cancertopics/factsheet/risk/brca (last visited Mar. 17, 2010).
13 Id
14 Id.
15 Id.
16 See id (showing that the test determines whether that mutation has been associated with
cancer in other people).
17 Id.
18 Complaint, supra note 2, at 13-14.
19 Id at 3-13.
2 Id at 2.
21 id
[Vol. 17:377
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allege these patents violate both the First Amendment and Article I, section 8,
clause 8 of the United States Constitution.' The plaintiffs also allege that these
gene patents violate "long established legal principles that prohibit the patenting
of laws of nature, products of nature, and abstract ideas." 3 As stated by the
ACLU's Science Advisor, Tania Simoncelli, "[Myriad Genetics owns] not only the
gene, they own any future tests, any future drug, any future therapy, so it means
we are putting our trust in one single company."24  Thus, the plaintiffs are
attacking four separate categories of patents held by Myriad: (1) patents on
"natural human genes"; (2) patents on "genes with natural mutations"; (3) patents
on "any method, including non-patented methods, of looking for mutations in
natural human genes"; and (4) patents over the "thought that two genes are
different or have different effects, including but not limited to the thought that the
differences correlate with an increased risk of breast and/or ovarian cancer. '25
The lawsuit notes the implications that these patents have on patients and
researchers.2 6 The plaintiffs allege that unlike other patents, gene patents do not
allow nonpatent holders to "invent around" the patents; their inability to do so
impedes scientific research.27 Because of these patents, the only supplier of
BRCAI and BRCA2 testing in the United States is Myriad Genetics. 8
Additionally, as the exclusive source of the test, Myriad Genetics holds a large
amount of data compiled through testing.2 9 Myriad Genetics has not, to date,
shared this database with the National Institute of Health's Breast Cancer
Mutation Database, which would "ensure the widest possible distribution of
information about genes and breast cancer."3  Thus, Myriad Genetics has
impeded access to information that could help researchers in future genetic
discoveries. The "chilling effect" of possible patent infringement enforcement
likely leads many researchers to refrain from conducting research on these patents,
possibly preventing future genetic breakthroughs.
3 1
Myriad Genetics, a Utah-based genetics company, won the race to find and
patent the BRCA1 and BRCA2 genes.32 The founder of Myriad Genetics, Dr.
2 Id at 3.
23 Id.
24 Liberate the Breast Cancer Genes, supra note 1.
2 Complaint, supra note 2, at 15.
26 Id. at 25-29.
27 Id. at 25.
28 id
29 Id at 26.
30 id
31 Id at 28.
32 Memorandum of Law in Support of Defendants' Motion to Dismiss at 3, Ass'n for Molecular
Pathology v. U.S. Patent & Trademark Office, 09 Civ. 4515 (S.D.N.Y. July 13, 2009), 2009 WL
3269109 [hereinafter Motion to Dismiss].
2010]
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Mark Skolnick, believes that Myriad has a right to the patents because the
company "[made] this huge multi-tens-of-millions dollars investment" so "don't
[they] have the right to deliver the test?' 33 And they do deliver the test, receiving
about 350 new samples per day.'" These samples are analyzed using one or both
of the two tests that Myriad performs: the comprehensive BRACAnaysis 5 test
and the expanded BART test.36 Dr. Skolnick claims that no women would have
been tested for the BRCA mutations if not for Myriad.3 He also states that the
commercial interest afforded to the company through the issuance of the patents
encourages the company to solve any problems that may arise.38 Myriad claims
that without patent protection the company would not have been founded because
the necessary funding would not have been made available by investors.39
Therefore, the plaintiffs asked: (1) that the patents granted to Myriad Genetics
for the BCRAI and BRCA2 genes be invalidated or deemed unenforceable, or (2)
that Myriad Genetics be enjoined from enforcing these patents.' On March 29,
2010, Judge Sweet, presiding over the District Court for the Southern District of
New York, granted the plaintiffs' motion for summary judgment, holding Myriad
Genetics BRCA1 and BRCA2 gene patents invalid.4' The day after the decision
was handed down, Myriad Genetics announced its plans to appeal the decision.42
Thus, the battle between the plaintiffs and Myriad Genetics is far from over, with
a final resolution of gene patentability likely years down the road.
This Note will consider the ways in which the patents granted to Myriad
Genetics have affected access to quality patient care, as well as the effect on
patient rights not only in the United States, but on an international scale. Part II
will examine how, under the current patent system, Myriad was granted a patent
on human genes, seemingly natural products. This Part will evaluate the decision
31 In the Family: A Visit to Myriad Genetics, http://www.youtube.com/watch.v=wffdTOT3
wgw (last visited Feb. 27, 2010).
3I4
s BRAC Analysis, BRCA Gene Testing, http://www.bracnow.com/ (last visited Feb. 27,2010).
3 Press Release, Myriad Genetics, Myriad Introduces Enhanced BRAC Analysis Test for
Exceptionally High-Risk Cancer Patients (Aug. 1, 2006), http://investor.myriad.com/releasedetail.
cfm?ReleaselD=325803.
"' In the Family: A Visit to Myriad Genetics, supra note 33.
38 Id
39 Motion to Dismiss, supra note 32, at 2. See alro Tamar Lewin, Move to Patent Cancer Gene Is
Caled Obstade to Research, N.Y. TIMES, May 21,1996, at A14, availabk athttp://www.nytimes.com/19
96/05/21/us/move-to-patent-cancer-gene-is-called-obstade-to-research.html (presenting the
opinion that without the prospect of a patent, investors would not invest in future research).
4 Complaint, supra note 2, at 30.
4 Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *6 (S.D.N.Y. Mar. 31, 2010).
42 Andrew Pollack, Taking Stock After Gene Patents ar Invaidated, N.Y. TIMES, Mar. 30, 2010,
http://www.nytimes.com/2010/03/31/business/31gene.html.
[Vol. 17:377
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of the District Court for the Southern District of New York; a decision which will
be appealed by Myriad Genetics in a fight to keep their gene patents valid. Part
II will then consider the handling of gene patents in other countries where Myriad
Genetics holds BRCA patents, including those of the European Union. Various
proposals that have been made by professional organizations and federal agencies
in the United States will also be discussed in the event Myriad Genetics wins on
appeal. Part III will examine the potential efficiency of these systems.
Additionally, this Part will look at how the court's resolution of this case could
affect gene patents in other countries. Part IV will address the insufficiency of the
current patent process for protecting the rights of patients in the United States and
worldwide. Part IV will also discuss options for possible agreements or standards
concerning gene patents that would address not only the concerns that have arisen
in the United States, but those that have arisen under the laws of other affected
nations.
II. BACKGROUND
A. DNA AND GENES: THE NATURAL BUILDING BLOCKS OF EVERY BODY
Each person has a unique genome, although 99% of a person's genome is
identical to that of any other individual.43 Each genome consists of genes, which
are sections of DNA that contain "instructions for making a specific protein or
set of proteins."'  DNA is the building block of each person's cells.45 It contains
a set of instructions that tell the cells in a living organism how to develop and
function." DNA is made up of four different nucleotides (those chemical units
that form the basis of the DNA molecule) codified as adenine (A), thymine (),
guanine (G), and cytosine (C).47 The order in which these nucleotides appear is
a naturally occurring phenomenon.' The arrangement of these nucleotides on the
DNA double-helix determines the traits a person will receive, as well as any
possible hereditary diseases a person may develop.' Genetic mutations occur
" National Human Genome Research Institute, A Guide to Your Genome (2007), http://
www. genome.gov/Pages/Education/AllAbouttheHumanGenomeProject/GuidetoYourGenome
07.pdf.
' National Human Genome Research Institute, A Brief Guide to Genomics, http://www.gen
ome.gov/18016863 (last visited Feb. 27, 2010).
45 Id
46 id
47 Id
' See id (demonstrating that these nucleotides systematically pair off to form the DNA
sequence).
49 Id
2010]
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where one or more of the aforementioned nucleotides is missing or out of
sequence5s These mutations may be inherited or may occur naturally during one's
lifetime."' Some of these mutations may have an impact on an individual's health,
increasing that person's risk for a variety of serious diseases, while others are
innocuous.52
Approximately 50/-10% of all women who develop breast cancer have a
BRCA1 or BRCA2 gene mutation. 3 Women who have one of these mutations
have a 400/o-85% risk of developing breast cancer at some time in their lives.5 4
About 150/6-40% of women with a BRCA mutation will develop ovarian cancer,
compared to 1.4% of the general female population. 5 The scientific community,
recognizing the indispensable benefit of genetic testing, has begun to intensify
focus on research in this area.
In order to read an individual's DNA sequence (the order of the As, Ts, Cs,
and Gs), a process called genetic sequencing is used.' Scientists and clinicians
regularly perform this sequencing process as part of their routine research.57 The
resulting sequenced gene "is informationally and functionally identical to the
sequence found inside the body," as none of the "informational content" of the
gene is changed during the sequencing process.5"
The process of sequencing a gene generally begins with the purification and
isolation of the gene. A purified gene is one that has been "isolated from its
natural state."59 An isolated gene is one "that has been removed from the body
and separated from surrounding cellular material."'  The sequence of the DNA
in the isolated and purified gene is the same as the sequence in the naturally
occurring gene.61 Thus, an isolated and purified gene is "functionally and
S0ld.
" See id (explaining that "[v]irtually every human ailment, except perhaps trauma, has some
basis in our genes"); see a/so Plaintiffs' Memorandum of Law in Support of Motion for Summary
Judgment at 2, Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515
(S.D.N.Y. Aug. 26, 2009), 2009 WL 3269113 [hereinafter Motion for Summary Judgment].
s2 National Human Genome Research Institute, supra note 44.
'3 Motion to Dismiss, supra note 32, at 3.
54 Id
s National Cancer Institute, supra note 13.
s National Human Genome Research Institute, spra note 44.
See id (explaining that researchers commonly perform a sequencing technique called "chain
termination method").
18 Plaintiffs' Rule 56.1 Statement of Material Facts at 15, Ass'n for Molecular Pathology v. U.S.
Patent &Trademark Office, 09 Civ. 4515 (S.D.N.Y. Aug. 26,2009) [hereinafter Plaintiffs' Statement
of Material Facts].
" Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (USPTO Jan. 5, 2001).
60 Motion for Summary Judgment, supra note 51, at 4.
61 Utility Examination Guidelines, supra note 59, at 1093.
[Vol. 17:377
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informationally identical to [the gene] in the body."'62 Under the current USPTO
Utility Examination Guidelines, an isolated and purified gene may be patented. 3
The genes at issue in the Myriad case have been labeled as isolated DNA.64
The sequencing of DNA for genetic testing purposes is not limited to the
breast cancer genes discussed here. Patents for genetic testing have also been
granted to individual companies testing for long QT syndrome, the HFE gene that
is linked to hereditary hemochromatosis, and the CFTR gene that is linked to
cystic fibrosis. 6' Thus, final resolution of the Myriad case could have far-reaching
effects on the entire biotechnology industry.
B. PATENT PROTECTION FOR BIOLOGICAL MATERIALS IN THE UNITED STATES
To be eligible for a United States patent, biological material, genetic or
otherwise, must meet three separate conditions: (1) it must be novel, (2) it must
have utility, and (3) it must be nonobvious.66 The USPTO is the entity
empowered in the United States to grant biological patents under these terms.67
Utility patents, such as those patents on the genes at issue in the Myriad case, are
valid for twenty years from the date of the patent application.6"
1. The Utiity Requirement Under 35 U.S.C. f 101. To meet patentability
requirements, a potentially patented item must have "utility."69 While the Supreme
Court has not historically held that the standard for utility is particularly high,7 ° the
Federal Circuit has held that the item must have "specific and substantial" utility
in order to be patented.7 The Court has not explicitly defined either "specific"
or "substantial" utility.72 However, the Federal Circuit, along with the Court of
Customs and Patent Appeals, provides that to meet the substantial utility
requirement "an asserted use must show that the claimed invention has a
significant and presently available benefit to the public."7 According to the
Federal Circuit, the patent application must have sufficient detail and "disclose a
62 Motion for Summary Judgment, supra note 51, at 4-5.
63 Utility Examination Guidelines, supra note 59, at 1093.
64 Motion for Summary Judgment, supra note 51, at 4-5.
65 John Schwartz, CaneerPatients Sue Testing Compaqy and Government over Gene Patents, N.Y. TIMES,
May 13, 2009, at A16.
6 Ramirez v. Perez, 457 F.2d 267, 269 (5th Cir. 1972) (citing 35 U.S.C. § 101-103).
67 United States Patent and Trademark Office, Our Business: An Introduction to the USPTO,
http://www.uspto.gov/web/menu/intro.htmil (last visited Feb. 27, 2010).
635 U.S.C. § 154(a)(2).
69 35 U.S.C. § 101 (2006) (requiring that the invention be "new and useful").
70 In re Fisher, 421 F.3d 1365, 1370 (Fed. Cir. 2005).
71 Id at 1371.
72 I d
73 Id
2010]
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use which is not so vague as to be meaningless" in order to be specific.7 4 Despite
being potentially useful for research purposes, if an application contains only
"hypothetical possibilities" that are not presently beneficial to the public, an
application may still be denied for not meeting the utility requirement."
The present benefit to the public is of particular concern to the biotechnology
industry, where the present public use of the gene or DNA sequence may not be
known at the time the patent application is filed. 6 This concern was addressed in
the USPTO's 2001 Utility Examination Guidelines, which states that a patent
application that "discloses only [the] nucleic acid molecular structure for a newly
discovered gene, and has no utility for the claimed isolated gene" cannot be
patented.7 However, if the application describes how the "purified gene isolated
from its natural state" will be used, and there is "specific, substantial, and credible
utility," then the utility standard is satisfied and the item may be patented.8
To further clarify this requirement, in 2001 the USPTO established a new set
of Utility Examination Guidelines for patent examiners to use when determining
whether the patent application meets the utility requirement under 35 U.S.C.
§ 101.7' Despite the title, the Guidelines tend to speak more to the novelty
requirement, however to correspond to the language used by the USPTO the term
"utility" will be used throughout this Note. When the USPTO requested public
comments regarding the proposed Guidelines, it received several comments
stating that genes are products of nature and as such do not constitute a "new"
entity." Others argued that isolating a gene does not equate to an invention or
discovery because genes are products of nature.8' The new Guidelines, rejecting
these arguments, state that isolated and purified genes may be patented despite the
fact that the isolated and purified gene has the same sequence of DNA molecules
as a natural gene would.82 The USPTO gave two alternate grounds for allowing
patents for isolated and purified genes: (1) the "DNA molecule does not occur
in that isolated form in nature," or (2) "synthetic DNA preparations" may be
patented because "their purified state is different from the naturally occurring
74 I
71 Id at 1373 (showing how the asserted uses of expressed sequence tags at issue in Fisher only
represented what coud be achieved).
76 3 STEVEN Z. SZCZEPANSKI, EcKSTRoM's LICENSING IN FOREIGN AND DOMESTIc
OPERATIONS § 13:14 (updated by David M. Epstein, 2009).
' Utility Examination Guidelines, supra note 59, at 1093.
78 Id
79 Id
80 Id
81 Id
82 Id
[Vol. 17:377
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compound." 3 The USPTO cited several cases to support its theory that the
patenting of isolated compounds was "weU-established."'  The Guidelines
primarily rely on Parke-Davis & Co. v. H. K Muford. In that case, the court found
a patent for adrenaline valid because it was isolated from nature; even though the
chemical was not changed from its natural structure, it was a new entity.' The
Guidelines additionally rely on In re Bergstrom.s7 In that case, the court found that
products extracted from prostate glands were patentable because the compounds
being patented did not naturally occur in a purified form. Thus, the applicants did
not simply discover the compounds, but invented them.' The USPTO does
make clear in the Guidelines that the standards for patenting, while covering
isolated and purified genes, do not expand patent protection to "cover the gene
as it occurs in nature."89
The USPTO directly addressed how DNA sequencing could be patented under
the new Guidelines.' The Guidelines state that the "fundamental sequence data,"
or the sequence of the As, Ts, Cs, and Gs, is not in and of itself patentable
because it is simply "nonfunctional descriptive information."'" However, the
Guidelines affirm that the "new and useful purified and isolated DNA compound
described by the sequence is eligible for patenting," as long as it meets all of the
other requirements of patentability.92 In light of the decision by the District Court
for the Southern District of New York in the Myriad case, however, the
Guidelines as they relate to gene patents are now invalid on their face.
2. History of U.S. Patent ProtectionforBiologicalMaterials. Whether or not a human
gene may be patented is a question of first impression. Up until this point, the
closest the Supreme Court has gotten to answering this question was in the
landmark case of Diamond v. Chakrabarny, which focused on the patentability of a
living organism.93 However, because a gene is not a living organism per se,
Diamond is distinguishable from the current controversy.
83 Id.
84 Id
85 196 F. 496 (2d Cir. 1912).
8 Parke-Davis & Co. v. H. K. Mulford, 189 F. 95 (S.D.N.Y. 1911).
- 427 F.2d 1394 (C.C.P.A. 1970).
88 Id.
'9 Utility Examination Guidelines, supra note 59, at 1093.90 id
91 Id.
92 id 
.
- 447 U.S. 303 (1980).
2010]
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Until 1980, the USPTO had not granted a patent on a living thing.94 However,
that changed with the decision in Diamond. In that case the Supreme Court was
asked to determine whether a "live, human-made micro-organism" could be
patented under 35 U.S.C. § 101.9' The Court determined that the live organism
at issue was patentable.96 After the Court's decision in Diamond, approximately
three million gene-patent applications were filed with the USPTO.97 Out of these
applications approximately 52,800 gene-related patents have been granted.9
Before Diamond, the case law concerning the patentability of biological
materials historically shied away from offering these materials patent protection.
A long line of cases, beginning as early as the late 1800s, have shaped the
patentability of biological materials, as well as addressed the effects of purification
of compounds on the product's patentability.
The vast majority of cases leading up to Diamond focused on the patentability
of materials that have been derived from natural products through extraction and
purification. The first such case arose in 1874 when the Supreme Court decided
American Wood-Paper Co. v. Fibre Disintegrating Co.' The Court voided the paper
company's patent for extracted wood-pulp, stating that the extract was the same
as the natural product."1 In a refrain that would be repeated throughout this line
of purification cases, the Court did note that the process for extracting the
material from the natural product may be patented if it is a new invention, "but
the thing itself when obtained cannot be called a new manufacture."'' The Court
came to a similar conclusion in Cocbrane v. Badiscbe Aniin & Soda Fabrik when it
held that a synthetic dye, even though it was being produced for the first time, was
not a new composition because it had the same chemical compound as the
original.' °2 The reliance on the purification doctrine became more apparent in Ex
parte Lafimer when the patent commissioner rejected a patent for fibers that were
extracted or purified from the needles of the longleaf pine tree.' °3 The
commissioner held that despite the purified nature of the fiber, the plant was still
9' Robert S. Boyd, Patenting Human Genes Thwarts Research, Sdentists Say, MCCLATCHY
WASHINGTON BuREAu, June 3, 2009, available at http://www.mcclatchydc.com/2009/06/03/69
373/patenting-human-genes-thwarts.html.
9 447 U.S. at 305.
96 Id at 313.
9' Boyd, supra note 94.
98 Id
99 90 U.S. (1 Wall.) 566 (1874).
100 Id at 596.
101 Id at 594.
102 111 U.S. 293, 311 (1884).
103 Application of Bergy, 596 F.2d 952, 982 (C.C.P.A. 1979) (citing Exparte Latimer, 1889 Dec.
Comm'r Pat. 123 (1889)).
[Vol. 17:377
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a product of nature and could not be patented °4 However, one lower court
challenged this precedent in Parke-Davis & Co. v. H. K Muford, Co., where it found
that an extract of adrenaline derived from the suprarenal gland was patentable.
10 5
The district court claimed the extract was separate from the gland from which it
was derived, and was different "not in degree, but in kind." 16
Despite this detour, other courts continued to abide by the Supreme Court's
decisions in the earlier purification cases, holding those materials unpatentable.
In GeneralElectric Co. v. De Forest Radio Co. the Third Circuit struck down a patent
for a purified form of tungstic acid."°7 While the company found a way to make
the naturally brittle compound more ductile, the district court held the patents
invalid because "they cover an element of nature with characteristics which nature
alone has given it."'08 The Third Circuit held that General Electric had not
discovered a new compound, but had simply discovered the natural qualities of
the pure form as it existed in nature."° In two additional cases with striking
factual similarity to GeneralElectric, an appellate court held that patents could not
be maintained on products that simply exposed the natural elements' hidden
qualities."
0
Similarly, the Supreme Court has continued to require that a product be novel
to be patented. In American Fruit Growers, Inc. v. Brogdex Co. the Supreme Court
found that the process of retaining the freshness of fruit through the use of borax
was not patentable."' The patent was voided for lack of novelty, because "[tihere
must be transformation; a new and different article must emerge 'having a
distinctive name, character, or use.' ,,12 In its decision, the Court noted that the
fruit itself retained the same form and possessed the same uses as it did prior to
the addition of the borax compound."3
Simply having a commercial advantage has also been held to be insufficient if
there is no enhanced utility or if the product is not novel. While a product may
be commercially valuable, the product cannot be patented if it is not novel."4 This
104 id.
105 Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 103 (S.D.N.Y. 1911).
106 Id.
107 28 F.2d 641, 642 (3d Cir. 1928).
108 Id.
109 Id. at 643.
"' See In r Marden, 18 C.C.P.A. 1046 (C.C.P.A. 1931) (finding a patent for ductile uranium void
because it was a product of nature); In re Marden, 18 C.C.P.A. 1057 (C.C.P.A. 1931) (finding a patent
for purified ductile vanadium void because it was a product of nature).
111 283 U.S. 1 (1931).
112 Id. at 13 (quoting Hartranft v. Wiegmann, 121 U.S. 609 (1887)).
113 Id at 12.
114 See In re Bergy, 596 F.2d 952, 982 (C.C.P.A. 1979) (quoting Exparte Latimer, 1889 Dec.
Comm'r Pat. 123, 125 (1889)) (finding that while the fiber extracted from the natural product was
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theory was reiterated in In re Mer,6 where the purified substance's brighter hue had
a slight commercial advantage for pigmentation purposes."' However, the patent
court held that despite any advantages of the purified form, if it does not have any
new utility the "product which has been purified is not patentable over the
unpurified product.""' 6 The Supreme Court weighed in on this discussion in Funk
Brothers Seed Co. v. Kalo Inoculant Co., where it held that a combination of natural
bacteria was not patentable despite its commercial advantage." 7 The Court found
that the aggregation of species did not constitute a new product because there was
no enlargement of utility."' The Court noted that while there may be certain
commercial advantages, a "product must be more than new and useful to be
patented; it must also satisfy the requirements of invention or discovery."
'
"
19
The most recent in this line of cases decided by the Supreme Court was
Diamond v. Chakrabarty in 1980.120 The Court was asked whether a man-made,
engineered bacterium capable of breaking down crude oil could be patented, or
whether it was a product of nature and unpatentable.' Looking at past
precedent, the Court reiterated that products of nature are not patentable."2
Providing a few examples, the court noted "a new mineral discovered in the earth
or a new plant found in the wild is not patentable subject matter."''13 Even if
useful, some theories and products cannot be patented. 24 Providing an example,
the Court noted, "Einstein could not patent his celebrated law that E=mc nor
could Newton have patented the law of gravity."' 25 In the case at hand, the Court
noted that to determine whether the bacterium could be patented, it had to decide
whether it was a " 'manufacture' or 'composition of matter' " under 35 U.S.C.
5 101.126 The Court determined that the bacterium had "markedly different
characteristics from any found in nature."" In a 5-4 decision, the Court held that
the organism claimed was not an "unknown natural phenomenon, but . . . a
nonnaturally occurring manufacture or composition of matter - a product of
commercially advantageous, it lacked novelty).
1' 97 F.2d 599, 601 (C.C.P.A. 1938).
116 Id. at 600.
117 333 U.S. 127, 131 (1948).
118 Id.
119 Id
120 447 U.S. 303 (1980).
121 Id at 309.
122 Id.
123 Id
124 Id. at 310.
25 Id. at 309.
126 Id at 307.
127 Id. at 310.
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human ingenuity."'" The Court held bacterium patentable deeming the creation
of a new bacterium a manufacture or composition of matter under 35 U.S.C. 5 101
and having found the requisite utility.1
29
As seen in the purification line of cases, the Court has typically refused to grant
patent protection to purified compounds. The cases have reiterated that patents
cannot be issued for products of nature, or products that simply uncover a
product's natural quality. However, they also demonstrate that a patent may be
granted on the process for purifying a compound if that process is new and
inventive." Even if the product has the potential of being commercially valuable,
if the product does not meet the requisite patent eligibility requirements the patent
will not be granted. 3' A product purified from a natural source is only patentable
if it has the required utility, and is different from the natural source from which
it was acquired.'
3. District Court Decision in the Myriad Case: The First Step Toward Gene Patent
Freedom.
a. The Myriad Genetics' Decision. The latest decision in the isolation and
purification line of cases came with the swift decision of the District Court for the
Southern District of New York in the Myriad Genetics case. On March 29,2010,
Judge Sweet granted the plaintiffs' motion for summary judgment, holding Myriad
Genetics' BRCA1 and BRCA2 gene patents invalid.'33 The decision invalidating
the gene patents stunned many lawyers who follow such issues. One such lawyer,
Rebecca S. Eisenberg, a law professor at the University of Michigan, stated, "it's
really quite a dramatic holding that would have the effect of invalidating many,
many patents on which the biotechnology industry has invested considerable
money."' 3 Judge Sweet summed up his decision by stating that "the identification
of the BRCA1 and BRCA2 gene sequences is unquestionably a valuable scientific
achievement for which Myriad deserves recognition, but that is not the same as
concluding that it is something for which they are entitled to a patent. '
128 Id. at 309.
129 Id. at 310.
t30 See, e.g., Am. Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. 566 (1874).
131 See, e.g., In re Metz, 97 F.2d 599 (C.C.PA. 1938); Funk Bros. Seed Co. v. Kalo Inoculant Co.,
333 U.S. 127 (1948).
132 See, e.g., Am. Wood Paper Co., 90 U.S. 566; Cochrane v. Badische Anilin & Soda Fabrik, 111
U.S. 293 (1884); ExParte Latimer, 1889 Dec. Comm'r Pat. 123 (1889).
13' Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *6 (S.D.N.Y. Mar. 31, 2010).
1' Andrew Pollack, After Patent on Genes Is Invalidated, Taking Stock, N.Y. TIMES, Mar. 30, 2010,
http://www.nytimes.com/2010/03/31/business/31gene.html.
13' Ass'n for Molecular Pathology, 2010 WL 1233416, at *135.
2010]
15
Pins: Impeding Access to Quality Patient Care and Patient Rights: How M
Published by Digital Commons @ Georgia Law, 2010
J. IN"4TELL PROP. L
Keenly aware of the breadth of any potential decision, the court named various
professionals, organizations, and other individuals whom invalidation would
directly affect."3 The court then outlined its decision by dividing the case into two
claims: (1) composition claims and (2) method (process) claims. 13 7
One of the first issues to be resolved by the court was the meaning of DNA.3
Myriad Genetics claimed that the plaintiffs' definition "suggests that the term
'DNA' refers merely to information," whereas Myriad argues it refers to "a real
and tangible molecule, a chemical composition."'39 The court sided with Myriad
Genetics noting that DNA is "a tangible, chemical compound."'" However, that
distinction did not save Myriad Genetics from ultimate defeat.
The bigger issue the court had to address was whether the composition "claims
directed to isolated DNA containing naturally-occurring sequences fall within the
products of nature exception to § 101." 1" The court first dismissed Myriad
Genetics' reliance on the Utility Examination Guidelines put forth by the USPTO,
arguing that they owe the USPTO's Guidelines "no deference"'42 and reiterating
that the courts have the ability to review patents granted by the USPTO (showing
the court's superior position over the decisions of the USPTO).'43 The court was
challenged with the application of the term 'isolated DNA.' The court noted that
Myriad's case was based on a mere "lawyer's trick."'" Lawyers have long claimed
that isolating DNA makes it patentable subject matter "by transforming it into
something distinctly different in character.""' However, the district court rejected
this argument. The court noted that DNA is different from many other chemicals
and compounds that are regularly patented because it is based upon information,
thus "represent[ing] the physical embodiment of biological information, distinct
in its essential characteristics from any other chemical found in nature.'
'1
Because these isolated genes are merely sources of information, the isolated nature
of the gene "neither [alters the] fundamental quality of DNA as it exists in the
body nor the information it encodes."'4 As a product of nature, the subject
" Id. at *3 (noting the "resolution of the resolution of the issues presented to [the Court] deeply
concerns breast cancer patients, medical professionals, researchers, caregivers, advocacy groups,
existing gene patent holders and their investors, and those seeking to advance public health").
137 Id. at *80.
13 Id at *90.
139 Id at *90-91.
140 Id at *91.
141 Id at *103.
142 Id. at *104.
143 Id. at *104-05.
144 Id. at *3.
145 Id.
146 Id at *3-4.
147 Id at *4.
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matter is not patentable under U.S.C. § 101.148 Verifying the contention of the
plaintiffs that a sequenced gene "is informationally and functionally identical to the
sequence found inside the body,"'49 the court held that the "sequencing process,
by design, does not alter the information content of the native DNA sequence."'
15
The court acknowledged that "purified or synthesized DNA may be used as
tools for biotechnological applications for which native DNA cannot be used,"''
but this useful feature of isolated genes does not elevate them to patentable
status.'52 The court lauded the effort and ingenuity Myriad put into isolating the
BRCA1 and BRCA2 genes, noting, however, that "the process and techniques
used were well understood, widely used, and fairly uniform insofar as any scientist
engaged in the search for a gene would likely have utilized a similar approach."'5 3
Thus, Myriad Genetics had done nothing new. They had not created a new form
of DNA by isolating it from the surrounding cellular material, and they likewise
did not create a new way to isolate such material.
The court focused on prior precedent to fortify its decision. While Chakrabar4y
instructs the court to interpret 35 U.S.C. § 101 broadly, the district court explained
that the broad scope of 5 101 is not without limits.'-" One such limitation is the
often-cited refrain of Chakrabarly and Diehr, both of which state that products of
nature are not patentable subject matter and as such "fall outside the scope of §
101."'15 Various courts have established the long history of this limitation
beginning with General Electric Co. and ending with Laboratoty Corp. of America
Holdings v. Metabolite Labs, Inc. In defining the scope of § 101, Judge Sweet relied
on In re Bergy and Diehr in concluding that novelty, subject matter, and utility are
all appropriate considerations under § 101.156 Thus, Judge Sweet subjected the
Myriad Genetics' patents to two tests: (1) "whether the claimed invention
possesses utility"; and (2) "whether the claimed invention constitutes statutory
subject matter."'5 7 The court found that the gene patents possessed utility, leaving
only the question of whether the genes "constitute statutory subject matter."'5 8
148 id.
9 Plaintiffs' Statement of Material Facts, supra note 58, at 15.
o As'nfor Moecuar Patology, 2010 WL 1233416, at *43 (S.D.N.Y. Mar. 31, 2010).
' Id. at *36.
12 Id. at *37.
13 Id. at *53.
154 Id. at *96.
155 Id. at *97.
156 Id at *101.
157 Id at *102.
158 Id.
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The court then determined whether the patentable subject matter was
"'markedly different' from a product of nature."'5 9 Myriad argued that neither
form of the isolated BRCA genes are found in nature,6 ° and furthermore relied
on Parke-Davis as the basis for the genes' patentability. 6 ' Relying on American Fruit
Growers, Funk Brothers, and Chakrabarty the court declared that a product must be
significantly different from its natural source in order to be patented. 62 The court
then addressed American Wood-Paper Co., which stood for the proposition that the
" 'purification' of a natural compound, without more, is insufficient to render a
product of nature patentable."' 63 Judge Sweet relied on Cochrane, GeneralElectric,
and Exparte Latimer for the same proposition."&I Based upon this precedent,
Judge Sweet held that Myriad Genetics' argument that genes are patentable subject
matter under relevant case law was incorrect. 65 He further noted that Parke-Davis
(the case on which Myriad Genetics relies) does not hold that "the purification of
a natural product necessarily renders it patentable" as claimed by Myriad
Genetics.'66 Rather, Parke-Davis dealt with a § 102 novelty issue, whereas the
current controversy hinges on a § 101 patentable subject matter theory.'67
Additionally the court noted that the portion of Parke-Davis upon which Myriad
based its argument was simply dicta after the central novelty issue was decided,
and is no longer good law after the Chakrabarli decision. 68 Judge Sweet also shot
down Myriad Genetics' reliance on two other cases, which speak to novelty
instead of patentable subject matter. 69 Summing up his argument, Judge Sweet
concluded that "purification of a product of nature, without more, cannot
transform it into patentable subject matter" and "the purified product must
possess 'markedly different' characteristics in order to satisfy the requirements of
§ 101."' ° Using this 'test' the district court ruled that the isolated DNA for which
Myriad Genetics holds patents is not patentable because it is not "markedly
different" from its natural source.'' The court did not agree with Myriad
Genetics' contention that isolated DNA is a chemical compound and thus can be
159 Id at *107.
'60 Id. at *113.
161 Id. at *114.
'62 Id at *107-10.
163 Id at *110.
164 Id. at *111.
165 Id at *113-14.
166 Id at *115.
167 Id. at *115.
'68 Id at *116.
169 Id. at *117-19 (showing Myriad Genetics' reliance on In re Brgslrom, 427 F.2d 1394 (C.C.P.A.
1970) and In reKrat
, 
592 F.2d 1169 (C.C.P.A. 1979)).
170 Id. at *121.
171 Id at *122.
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patented.172 The court differentiated DNA from other chemical compounds,
arguing that while they are chemical compounds they are also "physical carriers of
information.', 7 3 Because of this unique characteristic, the court found that it
"would be erroneous to view DNA as 'no different' than other chemicals
previously the subject of patents."'" 4 The court differentiated this case from
Parke-Davis stating that the information that DNA carries is not "its own
molecular structure incidental to its biological function . . . .Rather, the
information encoded by DNA reflects its primary biological function: directing the
synthesis of other molecules in the body," thus, DNA "serves as the physical
embodiment of the laws of nature."' 75 Because DNA is a law of nature under this
theory, it is not 'markedly different' making it unpatentable "6
The court did not rule on a few subjects that were part of the plaintiffs' original
complaint. Judge Sweet noted the plaintiff's issue of whether gene patents
"impact[ed] the testing for BRCA1 /2 mutations favorably or unfavorably," but
did not make a final decision on the matter saying it was an "issue of factual
dispute not resolvable in the context of the instant motions."'177 Judge Sweet also
noted the inability to resolve "disputes of fact and policy" under the motion when
he declined to rule on whether the gene patents at issue impeded the progression
of research and scientific knowledge noting the "sharp dispute concerning the
impact of patents directed to isolated DNA on genetic research and consequently
the health of society .... ,17' Additionally, Judge Sweet failed to address the
plaintiffs' constitutional claims, regarding them as irrelevant, considering Myriad
Genetics' patents were granted under the authority of 35 U.S.C. § lol.'79
A day after the decision was handed down Myriad vowed to appeal the
decision, noting that "even in the worst case for them, [it] would take years [for
the decision] to have a significant effect."'' " Myriad CEO, Peter Meldrum, said
the company was "disappointed that Judge Sweet did not follow prior judicial
precedent or Congress's intent that the Patent Act be broadly construed and
applied, [but Myriad is] very confident that the Court of Appeals for the Federal
Circuit will reverse this decision and uphold the patent claims being challenged in
this litigation."'' Additionally, Myriad Genetics holds sixteen more patents on
172 Id.
173 Id at *122-23.
174 Id. at "123.
175 Id at *124.
176 Id at *125.
177 Id. at *68.
178 Id. at *79.
179 Id. at *149 n.61.
180 Pollack, supra note 134.
181 Donald Zuhn, AMP v. USPTO: What the Parties are Saying About the Decision, PATENT DOCS,
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BRCA genetic tests that were not at issue in this case, leaving the company
revenue streams that are uninterrupted by this decision.' Several lawyers expect
the ruling to be overturned,'83 or at the very least "an important Supreme Court
showdown""' to ensure. Despite Judge Sweet's decision, the patentability of
genes is still a very real issue and the District Court's decision is nothing but
bandage for Myriad Genetics' patent problems. Until other courts take similar
measures, the reach of the current decision is severely limited.' At this point in
time the District Court's decision does not affect gene patents that were not at
issue in the current controversy (although should the decision be upheld on appeal
other patents will likely be challenged), thus the decision's precedential value for
other courts at this time is limited.' 86 This decision is hardly the end to the battle
over gene patentability, and as such other avenues for limiting gene patents'
breadth should be explored in the event that this initial decision is ultimately
overturned.
b. Public Response to the Myriad Genetics Decision. Many organizations and
commentators were unenthusiastic about the decision. Biotechnology Industry
Organization (BIO) President and CEOJim Greenwood released a statement after
the decision criticizing the holding and reiterating the patentability of genes:
From the mass production of life-saving medicines by cell cultures
to the screening of our blood supply for life-threatening viruses,
patented DNA molecules have been put to countless uses that have
benefited society. Preparations of isolated and purified DNA
molecules, which alone can be put to use in these ways, are
patentable because they are fundamentally different from anything
that occurs in nature.1
8 7
Likewise, IP attorney and blogger Eric Guttag finds fault with Judge Sweet's
interpretation of prior precedent and argues that the decision goes against earlier
Apr. 1,2010, http://www.patentdocs.org/2010/04/amp-v-uspto-what-the-parties-are-saying-about-
the-decision.html.
182 Id
183 Pollack, supra note 134.
184 PatentlyO, Court: Essenuial4 All Gene Patents are Invad, http://www.patendyo.com/patent/
2010/03/court-essendally-al-gene-patents-are-invalid.html (last visited Apr. 11, 2010).
185 Pollack, supra note 134.
186 Id.
17 Press Release, Biotechnology Industry Organization, BIO Statement On Initial Decision in
Myriad Genetics Lawsuit, Mar. 30,2010, available athttp://www.bio.org/news/pressreleases/newsi
tem.asp?id=2010_0330_02.
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Supreme Court decisions."s Guttag claims that Judge Sweet misinterpreted In re
Berg, which Guttag claims "actually supports the patent-eligibility of Myriad's
BRCA1 and BRCA2 gene sequence technology."' 89
Myriad attorney Brian Poissant argued to the court that "disallowing the
patents would wreck the foundation of the biotechnology industry."' 9 Judge
Sweet attempted to quell the fears of many that the decision would destroy the
biotechnology industry stating that the decision "concerning the subject matter
patentability of isolated DNA... [is] based on the unique properties of DNA that
distinguish it from all other chemicals and biological molecules found in
nature."' 91 In line withJudge Sweet's conclusion, the market for Myriad Genetics'
stock saw little effect from the decision, with analysts noting that the case may be
years from a final conclusion due to appeals.'92 Additionally, they note that while
other companies may eventually compete with Myriad Genetics in the testing
market, the competing products will likely not materialize for a while because
Myriad Genetics still holds other patents and the decision may still be reversed on
appeal. 93 Some fear invalidating these patents will hinder biotechnology
companies' ability to retain financial backers and "diminish the incentives for
genetic research."' 94 Kenneth Chahine, author of an amicus brief in support of
Myriad Genetics, claims that should the District Court's decision be upheld, the
"industry is going to have to get more creative about how to retain exclusivity and
attract capital in the face of potentially weaker patent protection."' 9' This is not
an issue that will cease in the near future. Biotechnology companies have much
to gain by protecting their patents, and much to lose in the face of the changing
landscape shaped by Judge Sweet's decision.
Commentators in favor of the decision addressed the issues of access, quality,
research, and cost in light of this decision. Noting the decision's effect on cost
and access, James Love, the American co-chair of the intellectual property
committee of the TransAtlantic Consumer Dialogue and director of Knowledge
's Eric R. Guttag, Foaming at the Mouth: The Insane Ruling in the Gene Patents Case, IPWATCHDOG,
Mar. 30,2010, http://www.ipwatchdog.com/2010/03/30/foaming-at-the-mouth-the-inane-rung-
in-the-gene-patents-case/id=9911/.
189 Id.
'90 Associated Press, US Judge Strikes Down Patent on CancerGenes, NATIONALPUBLIC RADIO, Mar.
30, 2010, http://www.npr.org/templetes/story/story.php?storyd=125326600.
'9' Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *123 n.51 (S.D.N.Y. Mar. 31, 2010).
192 Associated Press, Myriad Genetics Falls as Gene Patents are Voided, Bus. WK., Mar. 30, 2010,
http://www.businessweeklcom/ap/financialnews/D9EP20LO0.htm.
193 Id.
4 John Schwartz & Andrew Pollack, Judge Invalidates Human Gene Patent, N.Y. TIMES, Mar. 29,
2010, http://www.nytimes.com/2010/03/30/business/30gene.html?src=me.
195 Id.
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Ecology International, lauded the holding as "a very pro-consumer decision...
[that is] going to make it much cheaper for people to get the tests they need.'
'196
Addressing the issue of impeding research, President of the Association for
Molecular Pathology, Dr. Karen Mann, released a statement claiming "this
judgment removes numerous barriers and impediments to clinical research,
testing, and innovation."'1 97 Explaining the decision's effect on patient rights and
quality, Michael S. Watson, Executive Director of the American College of
Medical Genetics agreed "this is a huge, huge victory for better patient care" and
that the "invalidation of gene patents will allow patients to get second opinions on
test results, encourage quality improvement of current testing, allow researchers
to develop new and better methods of testing and decrease costs of laboratory
testing."' 95 Finally, the popular press, including the New York Times, noted the
potentially broad scope of the decision, stating that if Judge Sweet's decision is
upheld "the invalidation of genetic patents could hit diagnostics companies,
agricultural biotechnology companies and perhaps even traditional drug
makers."'99 Because of the sharp division this case has caused, as evidenced by
emotionally charged commentary following the holding by both camps, the war
for and against gene patents will be fought for years to come.
C. IMPLICATIONS FOR ACCESS, QUALITY, AND RESEARCH
Even with the potential positive effects the interim decision in the Myriad
Genetics case may have on access, quality, and research, evidenced by the positive
commentary of industry professionals, there is still strong opposition to the
interim decision. Should the appellate court overturn the ruling, access, quality,
and research will all be directly affected by the validation of gene patents. Thus,
it is important to discuss the substantial effect gene patentability has had on these
areas in the past.
196 Abigail Field, The Court Ruling That Says You Can't Patent Nature,'DAILY FINANCE, Mar. 30,
2010, http://www.dailyfnance.com/story/investing/the-court-ruhing-that-says-you-cant-patent-nat
ure/ 19420166/ (Love further states that gene patents "were anti-science, anti-innovation, and anti-
consumer').
197 Press Release, Association for Molecular Pathology, The Association for Molecular Pathology
Celebrates Ruling in DNA Patent Case (Mar. 31, 2010), available athttp://www.amp.org/PressRele
ases/GenePatentRuling-3.31.10.pdf.
198 Press Release, American College of Medical Genetics, American College of Medical Genetics
Lauds Federal Court Ruling of Gene Patents as Invalid (Mar. 30, 2010), available at http://www.
acmg.net//AM/Template.cfm?Section=Home3.
199 Pollack, supra note 134.
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1. Issue ofAccess. The issue of limited access is inherent whenever there is a
sole provider of a service.230 The patent protection afforded to Myriad Genetics
leaves no other option for patients whose health insurance is not accepted by
Myriad Genetics. 0 ' When proper testing is unavailable, these patients are left to
make medical decisions for themselves, without adequate information and with
little choice but to pay out-of-pocket for the test. One may argue that it is the
insurance companies and social issues, such as poverty, that limit access to these
tests, and patients' limited access is not the fault of the patents granted to Myriad
Genetics. However, if the patents remain void, other companies could enter the
testing market allowing insurance carriers a broader choice. The more providers
that are available, the more likely an individual's insurance will cover at least one
of these testing facilities, leading to broader access overall.
Patent protection also limits patients' access to a second opinion. The ability
of a patient to seek out an independent second opinion is an important part of the
medical process. 2 Should the test performed by Myriad Genetics come back
inconclusive, a patient has no choice but to accept this finding at face value. 3
While additional testing may be performed, the additional BART test is not
covered by the initial fee, and some insurance providers may not cover the
increased cost of testing.20' Even with additional testing, mutation identification
based on Myriad Genetics' data may not be available, considering the information
contained in Myriad Genetics' databank has been shown to be inconclusive in a
small percentage of cases.0 5 Patients who receive inconclusive results have little
free choice. Their options are limited to paying Myriad Genetics to perform the
second test, which may not lead to additional information, or accepting the
inconclusive results. 6 Accepting inconclusive results, without the ability to
further identify the issue, may be detrimental to a patient's health. Without proper
gene identification, medically uneducated patients are left to make life-altering
medical decisions, such as whether or not to undergo preventative measures to
200 Complaint, supra note 2, at 10 (presenting the case of Lisbeth Ceriani, whose insurance was
not accepted by Myriad and thus remains untested).
24 Id. at 27 (showing that two plaintiffs whose insurance was not accepted by Myriad are left to
pay out-of-pocket for the test).
202 Seegeneraly Patient Advocate Foundation, Second Opinions, http://www.patentadvocate.org/
index.php?p=691 (last visited Mar. 18, 2010) (educating patients on the importance of second
opinions).
203 Complaint, supra note 2, at 11 (demonstrating the problem that two plaintiffs encountered
when they received inconclusive results).
24 Id at 27-28 (stating that additional BART testing costs approximately $650 when not covered
by insurance).
25 Id. at 26.
206 Id. at 27 (describing the expanded BART test or the alternative of no additional testing).
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avoid the development of cancer, based on little concrete information. The wrong
choice may make the difference between life and death.
2. Issue of Quaky. Quality concerns have also become a large part of the
genetic testing debate. By several accounts, the test that Myriad Genetics provides
could be improved significantly. One French study suggests that Myriad Genetics'
testing procedure fails to find 100/o-2 0% of mutations."° Other tests that have
been precluded from entering the market because of Myriad Genetics' patents may
have the potential of providing more accurate results in certain circumstances.
208
3. Issue of Impeding Research. Most significantly, prior to Myriad securing the
relevant patents, several scientists and researchers were conducting research on
BRCA genes.20° However, when confronted with potential liability for their
research activities, these researchers stopped their research. 210 Because the actual
genes and gene mutations are protected by the patents, researchers are unable to
conduct research on the patented genes or any mutations thereof. This
prohibition operates even if the actual test they are conducting is not the same
typeas the test conducted by Myriad Genetics. There is currently no workaround
for researchers.21 The plaintiffs believe that research and testing will be stifled
unless the appeals court upholds the District Court's decision to void Myriad's
gene patents. While Myriad Genetics claims that it is not currently targeting
researchers, many researchers are aware of instances where Myriad Genetics
sought enforcement of the company's patents. 12 If researchers are not able to
research the BRCA genes, the gene information available will remain woefully
inadequate.
D. PATENT PROTECTION IN EUROPE AND THE EUROPEAN PATENT OFFICE'S
TREATMENT OF MYRIAD GENETICS
The European Patent Office (EPO), a division of the European Patent
Organisation, is a centralized body that grants patents for up to forty European
countries.213 The requirements for EPO patents are similar to those of the
' Steve Benowitz, French Challenge to BRCA 1 Patent Underes European Discontent, J. NAT'L
CANCER INST.,Jan. 16,2002, at 80-81, avaiabkathttp://jnci.oxfordjournals.org/cgi/content/full/
94/2/80.
20 Plaintiffs' Statement of Materials Facts, sApra note 58.
209 Id. at 3-5.
210 Id. at 34-35.
211 Id. (arguing that gene patents inhibit research because researchers are not able to conduct any
testing on BRCA genes due to the patents).
212 Id at 26-28.
213 European Patent Office (EPO), About Us, http://www.epo.org/about-us/office.html (last
visited Mar. 2, 2010).
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USPTO. Under Article 52 of the European Patent Convention (EPC), a
patentable invention is one that is (1) new, (2) "involve[s] an inventive step," and
(3) has an "industrial application. '214 Patented goods are granted up to twenty
years of protection from the date in which they are granted."
Under the European Union Biotech Directive isolated biological material is
patentable "even if it previously occurred in nature., 216 Thus, a human gene
sequence may be patentable "even if identical to the natural element., 217 A human
gene sequence that has been isolated from its natural surroundings, or isolated
DNA, is included as patentable subject matter under the directive. 21 ' Diagnostic
tests, which use DNA, have also been held to be patentable.2 9
After a patent has been granted by the EPO, third parties have the opportunity
to oppose the patent in a formal opposition procedure if they believe that the
patent should not have been granted.' 2 One reason that an opposition may be
filed is if "the subject-matter of one or more of the claims is not new or
inventive."" The opposition division of the EPO will then investigate the basis
for the opposition.' Upon completion of this investigation, the opposition
division may revoke the patent, maintain it, or maintain it in an amended form.'
The EPO granted Myriad Genetics four patents in 2001." One of these
patents covered the "method for diagnosing a predisposition for breast and
ovarian cancer.""2 In particular, this patent covered mutations of the BRCAI
gene and the gene mutations' use in determining whether an individual was at an
increased risk of breast or ovarian cancer. 6 This patent generated many critics."
214 European Patent Convention, art. 52, Oct. 5, 1973, 1065 U.N.T.S. 199.
215 EPO, Patent Teaching Kit 14 (2009), http://documents.epo.org/projects/babylon/eponet.
nsf/o/e32dOd43d34f5681c125763cOO54b3bb/$file/patentteachingkit__en.pdf.
216 Council Directive 98/44, art. 3, 1998 O.J. (L 213) 13-21 (EC).
217 Dr. Siobhfin Yeats, Workshop on Biotech Patents, Sept. 20,2007, http://documents.epo.org/proj
ects/babylon/eponet.nsf/0/98a8f52d28939beec125735dOO51c409/$file/biotech-workshop20
07_yeats.pdf.
218 See Directive, supra note 216.
219 Yeats, supra note 217.
2 EPO,The Opposition Procedure, http://www.epo.org/about-us/jobs/examiner/role/oppo
sition.hunl (last visited Feb. 27, 2010).
221 Id.
22 Id.
22 Id.
224 European Patent Nos. 699 754 (filed Aug. 11, 1995); 705 903 (filed Aug. 11, 1995); 705 902
(filed Aug. 11, 1995); 785 216 (filed Dec. 17, 1996).
' European Patent No. 699 754 (filed Aug. 11, 1995).
22 Id
"2 See Press Release, EPO, Public Opposition Hearing on "Myriad/Breast cancer" Patent at the
European Patent Office (May 12, 2004), availabk athttp://www.epo.org/about-us/press/releases/
archive/2004/15052004.html (showing that several organizations, including the Institut Curie, filed
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In October of 2001, the Institut Curie filed an opposition with the EPO
challenging European Patent No. 699 754.m Five additional letters of opposition
were also filed by other interested organizations. 29 The Institut Curie claimed that
the patent did not meet the novelty requirement under Article 52 of the EPC,
lacked an inventive step, and contained an insufficient description.' Additionally,
the Institut argued that the patent at issue might "jeopardize the development of
research, hinder access to testing, and furthermore go against [Europe's] approach
to public health."23' Finally, Institut Curie claimed that the patent granted was too
broad. 2 The patent would prohibit labs that were already conducting research
from continuing their research on these genes in Europe, regardless of the testing
procedure used.2 33 The Institut further noted that Myriad's sequencing fails to
detect 10% to 20% of all mutations, leaving room in the market for improvement
using a different type of gene sequencing than Myriad uses.' After the
opposition hearing on May 18, 2004, the EPO revoked the opposed patent,
European Patent No. 699 754.235 The opposition division found that the patent
violated Article 56 of the EPC requiring an inventive step.23 6 Myriad Genetics
challenged the revocation, and in a second hearing the patent was maintained in
an amended form. 1 7  The amended patent protects only certain diagnostic
formal opposition letters with the EPO regarding the patent).
2M Id.
' Opposing Organizations included: (1) Assistance Publique-Hospitauxde Paris; (2) Institut
Gustave Roussy-IGR; (3) Beligian Society of Human Genetics Dpt. Hop.; (4) Azienda Ospedaliera
Materdomini Nella Persona Del; (5) Associazione Angelaserra per la Riccerca Sul Cancro. EPO,
Register Plus, https://register.epoline.org (search Application No. 95305602; view Oppositions).
o Press Release, Institut Curie, Against Myriad Genetics's Monopoly on Tests for
Predisposition to Breast and Ovarian Cancer, the Institut Curie is Initiating an Opposition
Procedure with the European Patent Office, Sept. 12, 2001, avai/abk athttp://www.curie.fr/upload/
presse/myriadopposition6sept0lgb.pdf.
231 Id.
232 Id.
233 Id.
2 Id.
35 Press Release, EPO, "Myriad/Breast Cancer" Patent Revoked After Public Hearing (May 18,
2004), http://www.epo.org/about-us/press/releases/archive/2004/18052004.html.
' Press Release, Instirut Curie, Contesting the Monopoly of Myriad Genetics on Testing for
Predisposition to Breast and Ovarian Cancer- A Shift in Position at the European Patent Office
(Nov. 20,2008), http://www.curie.fr/upload/presse/Myriad-Genetics-predisposition-breastt-cance.
pdf.
"37 Press Release, EPO, Board of Appeal Confirms Amended Patent on Breast and Ovarian
Cancer Susceptibility Gene after Public Hearing (Sept. 27, 2007), http://www.epo.org/about-us/pre
ss/releases/archive/2007/20070927.htrml.
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methods. 3  While overall a victory for those that opposed the patent, the
amended form still includes about half of known mutations.239
There was also a formal opposition process to two other Myriad Genetics
patents granted in 2001.2 European Patent No. 705 902, which was related to
the actual BRCA1 gene, was "maintained in a severely limited form. 2 41 European
Patent No. 705 903, which covered "[m]utations in the 17q-linked breast and
ovarian cancer susceptibility gene," was also maintained in an amended form after
being limited during its first opposition hearing in 2005.242
E. SUGGESTIONS FOR CHANGE
1. National Institutes of Health. The National Institutes of Health (NIH), a
subdivision of the Department of Health and Human Services, developed a series
of recommendations that it released as its Best Practices for the Licensing of Genomic
Inventions in 2005.243 NIH recommends several possible solutions, some of which
conflict with each other. The NIH's guidelines first suggest that gene patents be
granted only "when it is clear that private sector investment will be necessary to
develop and make the invention widely available." 2' In contrast to the
aforementioned recommendation, the NIH condemns the use of gene patents
when "significant further research and development investment is not required."245
As a compromise to the above recommendations, the NIH suggests several
licensing standards that borrow aspects from both. NIH's best practice is to
encourage the use of non-exclusive licenses whenever possible." If non-exclusive
licensing is not feasible, then the NIH concedes that an exclusive license may be
used but should be "tailored to ensure expeditious development of as many
aspects of the technology as possible." '247 NIH's overall goal with respect to its
best practices is to ensure continued access to new technologies for the public
health.2 4 Restricting the use of gene patents would be ideal, however, ensuring
238 id.
2 Institut Curie Nov. 2008 Press Release, supra note 236.
240 Press Release, EPO, Technical Board of Appeal Maintains Two "Myriad/Breast Cancer"
Patents in Limited Form (Nov. 19,2008), http://www.epo.org/topics/news/2008/20081119.htm.
241 id
242 Id.
243 Best Practices for the Licensing of Genomic Inventions: Final Notice, 70 Fed. Reg. 18,413
(Apr. 11, 2005).
24 Id. at 18,415.
245 id
246 Id (allowing non-exclusive licensing would permit others to legally use patented material
within the scope set forth in the licensing agreement).
247 id
248 Id.
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the public availability of genes through licensing would be an acceptable
compromise for the public as well as the biotechnology industry.
2. Secretay's Advisory Committee on Genetics, Health, and Sodety. The Secretary's
Advisory Committee on Genetics, Health, and Society (SACGHS), an advisory
committee to the Secretary of Heath and Human Services, released a draft report
for public comment in June 2009 outlining several issues regarding gene patents
and presenting ways to improve the patenting of genes. 49 SACGHS's report
described several concerns related to gene patents, finding some had merit while
others lacked sufficient evidence upon which to form a solid conclusion at the
time of publication. SACGHS first addressed access concerns, concluding that
gene patents create several patient access problems.' The access problems that
arose were mainly due to the sole provider: (1) not providing the test, (2) not
offering "complete testing of alleles and rare genes," and (3) not contracting with
certain payors (often third party insurers).,5 ' SACGHS did note, however, that
while patents "may limit clinical access to a test," that does not directly correlate
to "limited patient access to a test.
2 2
SACGHS's main concern was the effect of gene patents on continued research
and development. 3 From a research and development standpoint, SACGHS
found that the "prospect of receiving a patent was not the major force motivating
scientists.' '2 ' SACGHS argues that many scientists in the genetic field will
continue to carry on their research regardless of patent protection for a variety of
other reasons, the most compelling of which is "clinical need.2 55 However, the
SACGHS did note the importance of patents to the eventual commercialization
of a genetic test.2 1 SACGHS's main concern within the research realm was the
potential problem that could manifest itself in "multiplex genetic testing" and
"whole genome analysis/sequencing," where the use of several potentially
patented genes would be required.27 SACGHS noted that the cost of purchasing
several licenses to conduct testing may be cost-prohibitive for many researchers.5 8
249 Secretary's Advisory Committee on Genetics, Health, and Society, Public Consultation Draft
Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic
Tests, Mar. 9,2009, http://oba.od.nih.gov/oba/SACGHS/SACGHS%20Patents%/20Consultatio
n%20Draft/o203/o209/202009.pdf.
Id at 109.
2s' Id.
252 Id.
253 Id at 99.
254 id
SId. at 111.
5 Id. at 100 (noting that although patents are not "uniformly a necessary incentive" to develop
genetic tests, they may be necessary to encourage development of tests with "rare alleles").
2s7 Id. at 106.
2% Id
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Furthermore, if the patent holder did not allow licensing at all, further testing with
that gene would be impossible.
Taking the aforementioned findings into consideration, the SACGHS
proposed several policy changes including: (1) increasing involvement of
shareholders, (2) increasing transparency, (3) broadening licensing efforts, and (4)
making statutory changes.2" SACGHS first recommends that stakeholders
cooperate in order to "develop a code of conduct to encourage broad access."'
When there is a collaboration of stakeholders, such as private firms and university
researchers working together on a product, these entities should plan in advance
how issues such as patents and licenses will be addressed to avoid future
conflict. 6
SACGHS then suggests increasing transparency in the patent and licensing
process.262 One suggestion in this arena is to encourage patent holders to make
information about their licensing standards public.' SACGHS also suggests
having the Food and Drug Administration and Medicare/Medicaid require genetic
testing companies to display patent numbers on their product or website before
the company could market the product.2' Based upon its recommendations, it
appears that SACGHS's focus is to make information on these patents easily
accessible for others to find, leading to the possibility of increased communication
and cooperation between the parties.
Third, SACGHS recommends having federal agencies promote broader
licensing practices among patent holders to help ensure continued access of these
tests to patients.6" SACGHS noted several organizations' licensing guidelines as
a starting point for federal agencies to abide by in pushing broader licensing
practices but did not settle on one particular scheme.2" Suggestions include
federal agencies promoting the use of exclusive licensing for genetic inventions
and promoting licensing for "development and use" for "neglected patient
populations." 67 Additionally, SACGHS suggests that federal agencies look into
new methods of dissemination of technologies including patent pooling and due
diligence clauses in licensing agreements as potential answers to the access issue.26
259 Id. at 113-23.
26 Id. at 113.
261 Id. at 113-14.
262 Id. at 115.
263 Id.
264 Id
26' Id. at 118.
6 Id. at 118-19 (looking at licensing schemes promulgated by the NIH, OECD, and AUTM).
267 Id
268 Id at 119.
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Most importantly, SACGHS suggests statutory changes that could improve the
current patenting of genes.269 Notably, SACGHS suggests limiting "patenting of
diagnostic tests that rely on an association of a particular genotype with a
disease/disorder," or, alternatively, only allowing these patents with conditions
and scope limitations. 7 ' Reaching beyond researchers, SACGHS also suggests
limits on infringement liability for "medical practitioners who .. .perform
diagnostic genetic tests in clinical care," and those who perform "diagnostic
genetic tests in the pursuit of research.' ' "l While other organizations recommend
eradicating gene patents completely, SACGHS's recommendations target ways to
improve the current gene patent system by focusing on the availability of licensing
information and making exceptions for uses in the public interest.
3. Organisation for Economic Co-Operation and Development. In 2006, the
Organisation for Economic Co-Operation and Development (OECD), an
international forum, proposed new licensing guidelines for genetic inventions. 72
The OECD presents a unique perspective on gene patenting, as it represents the
interests of stakeholders from around the world. 273 The interested parties agree
that licensing may resolve many of the fears related to gene patents.274 The overall
goal of the OECD's guidelines is to ensure availability of genetic testing by
licensing inventions to assist in the "rapid dissemination of information," while
still allowing the original patent holder to make a return on his investment.275
Specifically, the OECD recommends that rights holders "broadly license genetic
inventions for research and investigation purposes" to ensure the widest public
access to the inventions.276
The OECD seeks to limit licensing, stating that "exclusive control over human
genetic information" should not be maintained by the licensor and licensors
should license their genetic invention as to maximize its utilization.277 To combat
the possible impediment of research, the OECD focuses on continued
development, ensuring that licensing agreements allow licensees to improve upon
269 Id at 122.
270 id
27' Id. at 123.
272 Organisation for Economic Co-Operation and Development (OECD), Guidelines for the
Licensing of Genetic Inventions (2006), http://www.oecd.org/dataoecd/39/38/36198812.pdf.
" The OECD member countries are: Australia, Austria, Belgium, Canada, the Czech Republic,
Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Japan, Korea,
Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, the Slovak Republic,
Spain, Sweden, Switzerland, Turkey, the United Kingdom, and the United States. Id at 2.
24 Id. at 3.
2s Id. at 7.
276 Id. at 9.
277 Id. at 8.
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the invention.27 As additional protection, the databases that hold the information
derived from continued research on the invention should not be restricted or
solely controlled by the licensor, but widely disseminated.79 With a focus on
balancing the commercial and research issues that arise with gene patents, the
OECD suggests that the commercial value of the gene should not unduly affect
the work of academic researchers.' Should royalty payments be necessary, they
should be reasonable."s In addition to licenses, the OECD also suggests that
"research deference" or a research exception be provided where allowed by the
individual jurisdiction. 28' Essentially, the OECD is concerned with producing the
least restrictive licensing scheme possible to ensure the public's access to these
important inventions while still keeping the patent holder's interests in mind.23
III. ANALYSIS
Under the current gene patent standards, Myriad Genetics has the USPTO's
Guidelines on its side, however the current law is not. While research suggests
that gene patents may not be the sole cause of limited access or increased cost of
genetic testing, it is still a relevant consideration. The actions taken in response to
the Myriad case will likely change the face of gene patenting from this day forward.
Thus, the legal community must be aware of the practical implications of the
current controversy. This case extends far beyond the named plaintiffs; it extends
to all people who have a family history of genetic disorders who wish to be tested,
and to all of those who will be refused a second opinion when the sole provider
of the test refuses to license it. To allow a company to profit off of nature at the
expense of the public health should not be permitted by the USPTO, but that is
exactly what the current Utility Examination Guidelines allow. The patents issued
by the USPTO deprive women of the right to take control of their own health for
the length of Myriad's patent protection, while protecting the company that is
depriving these women of this right. Myriad Genetics has been hiding behind its
patent while exploiting patients in their time of greatest need.
This is not simply the economics of allowing a company to recoup its research
and development costs through patents. This case is about inserting humanity
back into the patent process, and using the patent process to protect those who
need it the most, the public. It would be ideal if the appellate court would uphold
278 Id.
279 Id at 9, 16.
m Id at 10.
281 Id at 11.
2 Id at 18.
SId at 11.
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the decision of the District Court for the Southern District of New York, ensuring
that Myriad Genetics' BRCA patents remain void. However, in the event the
decision is overturned, a very real possibility, steps must be taken to protect the
public to ensure continuing access, quality, and research for all. Additionally, there
are still thousands of gene patents that were not subject to this suit, which are
linked to numerous genetic diseases and disorders. Any final decision in the
Myriad Genetics case, be it for or against gene patentability, will reverberate across
the industry. Should the Myriad case be overturned and the relevant patents held
valid, the policymakers' focus should shift toward limiting or narrowing the scope
of gene patents. The suggestions made by various organizations and the example
set by the countries of the EU should be viewed with an eye toward limiting gene
patents. If gene patents are ultimately held valid, limitations should be put on
patenting isolated and purified genes and the related gene mutations linked to
specific diseases, or, alternatively, all current gene patents should be revoked. This
is not to say that a company is completely left without reward for its discovery.
The best option for all parties involved is to deny patents for genes, but to allow
them for the testing process. Additionally, other yet undisclosed or undiscovered
options for dealing with gene patents may be available through legislation and
regulation.
This Part will discuss how the current USPTO Utility Examination Guidelines
should be amended. It will then examine how to close the gap between the needs
of these for-profit corporate entities and the needs of current and future patients
should the Myriad decision be overruled. Next, this Part will take suggestions
from recently released reports and evaluate the practicability of those suggestions.
In conclusion, this Part will evaluate whether the actions taken by the EPO could
work in the United States.
A. CHANGING THE USPTO'S UTILITY EXAMINATION GUIDELINES
The District Court noted the USPTO's Utility Examination Guidelines in its
decision, and dismissed Myriad Genetics' reliance on them.8 The Court stated
that it owed the USPTO's Guidelines "no deference," and as such the current
Utility Examination Guidelines may be of little practical value."s However, should
the Myriad decision be overturned on appeal, the Guidelines will once again be in
force. Thus, it is important to evaluate changes that could be made to the
Guidelines to limit gene patents, despite the Guidelines' current status.
' Ass'n for Molecular Pathology v. U.S. Patent & Trademark Office, No. 09 Civ. 4515, 2010
WL 1233416, at *104-05 (S.D.N.Y. Mar. 31, 2010).
2 8 d.
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One option that may be implemented to protect the public health is to revise
the current Utility Examination Guidelines. As they currently stand, any gene that
is found, isolated, and purified can be patented. 286 Thus, theoretically, the
Guidelines would grant protection to any gene found in the human genome.
What happens when research is halted because a patent holder refuses to allow
researchers access to the gene? New discoveries that could help millions are at
risk. Genes that are currently being patented are related to a number of
debilitating diseases. 28 In order to continue research on unpatented genes, access
to patented genes may be necessary in order to establish how one gene reacts with
another to produce a given ailment.88  Without reevaluating the Utility
Examination Guidelines, the ability of researchers to continue their research on
genetic diseases will continue to decline.
Because the Guidelines are in a state of limbo in light of the current
controversy, it is difficult to determine exactly what type of changes would be
most beneficial. If the District Court's decision is upheld, the lack of deference
afforded to the Guidelines by the courts will force the USPTO to redraft the
Guidelines to comport with the appellate decision. However, if the case is
overturned on appeal, the USPTO should implement a limiting principle into the
current Guidelines to further narrow the scope of any gene patents that are
granted. Either way the current broad scope of the Guidelines must be addressed,
be it by judicial decision or the USPTO's own pen.
B. HOW TO CLOSE THE GAP BETWEEN THE NEEDS OF THE CORPORATION AND
THE PATIENT
One major objective in granting patents is to allow inventors to reap the
financial benefits of their discovery."n While public health must be protected, the
courts and legislature must not forget about the need to incentivize innovation.
Generally, without the prospect of commercialization, financial backers would not
invest in genetic research. 9 ° In fact, the owner of Myriad Genetics claims that
without the promise of a patent, the research that led to the discovery of the
See supra note 92 and accompanying text.
2 See supra note 65 and accompanying text (describing patents for long QT Syndrome,
nemochnomatosis, and cystic fibrosis).
' See supra notes 257-58 and accompanying text.
2'9 See U.S. CONST. art. I, § 8, Cl. 8 (stating that patents are available to "promote the Progress
of Science and useful Arts, by securing for limited Times to Authors and Inventors the Exclusive
Right to their respective Writings and Discoveries").
' See supra note 39 and accompanying text (showing how Myriad would not have had the
resources to discover the BRCA genes without the prospect of commercialization).
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BRCA genes would never have occurred." The question then remains, how can
one close the gap between the needs of the public and the needs of the
corporation? Several organizations have made suggestions in regards to fixing the
current gene patent problem, should the Myriad decision be overturned.
1. Licensing Reform. One suggestion the NIH presented in its Best Practices for
the Licensing of Genomic Inventions is non-exclusive or exclusive licensing for genetic
materials. 2 While the NIH noted the importance of prospective patents to the
eventual commercialization of a product, and suggests that patents be available
when necessary to ensure wide distribution of the product, it also noted the
importance of licensing as a limitation on the patent.293 If non-exclusive licensing
is not possible, then NIH suggests that exclusive licensing be used.24 Additionally
SACGHS suggests that federal agencies promote broader licensing practices to
ensure continued access to patients.295 Both of these suggestions would work to
close the gap between what the company needs to commercialize its product,
while protecting the public. Statutorily requiring compulsory licensing for genetic
materials is one way to handle the current dilemma. The licensing of patented
genetic inventions would take care of many issues that arguably face this industry,
including lack of access, lack of quality, and impeded research. Even if a company
is required by statute to license out its invention, it would still reap the financial
benefits that come from the patent protection. Statutorily mandated compulsory
licensing is also advantageous for the consumer, because it ensures access to the
product. Additionally, because more than one company would be conducting the
testing, the quality of the test could be verified, leading to more accurate results.
Lastly, statutorily based compulsory licensing ensures that research on these genes
continues. While the cost of procuring a license may still be prohibitive for some
researchers, simply having the ability to work with a gene through a license is
better than not having access to the gene at all. Statutorily required compulsory
licensing would not alleviate all of the issues that are currently plaguing gene
patents. However, it may help in securing the financial rewards that companies
need while protecting access and quality for the public, and allowing continued
research for all.
The OECD agrees that changes in licensing must occur, and detailed its
findings in its Guidelines for the Licensing of Genetic Inventions.296 Unlike the broader
statutorily based compulsory licensing scheme of the NIH, the OECD argues that
291 See supra notes 37-39 and accompanying text.
292 See supra Part ILE. 1.
293 See supra Part II.E. 1.
' See supra note 247 and accompanying text.
295 See supra Part II.E.2.
296 See supra Part II.E.3.
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the best way to ensure access to genetic testing, while keeping companies' interests
in mind, is to encourage biotechnology companies to license broadly for "research
and investigation purposes." 7 OECD's model recommends that any royalty
payments made by researchers be reasonable, thus making it financially practical
to conduct their research."8 In an ideal world, the OECD suggests that there be
a research exception that would allow research to be conducted without charge.
299
This would ensure that research continues while still allowing the patent holder
to conduct the actual testing. This suggestion would benefit both the patent
holder and the public. The patent holder would remain in control of his
invention, while research could continue to benefit the public. However, the
practicability of this recommendation is slim at best. If biotechnology firms are
already refusing to license their invention, it is unlikely that the mere suggestion
that they do so in the name of research would change their minds. In order for
a biotechnology company to take the financial risk of licensing its invention to
researchers with little or no royalty payments, there must be an incentive for the
company. The company must be able to recoup its lost profits through alternate
means, possibly in the form of tax breaks or grants for further research. Without
such an incentive scheme in place, the likelihood that a company would be willing
to part with the control and financial resources that come with being a sole
provider is slim.
The OECD's suggestion is not as favorable to the public as statutory
compulsory licensing. Compulsory licensing lends itself well to quality control
because other laboratories would also be conducting testing. Without compulsory
licensing this quality control is not realized. Under OECD's model, however, the
license would allow licensees to improve upon the invention. 3°° While not directly
related to the day-to-day quality control of the test, this proposal may help in
increasing the quality of the test as a whole. It would allow others to build around
the invention to create a better and more accurate test. The access and cost
benefits of compulsory licensing are also not as apparent under this scheme.
Because other laboratories would only be engaged in research and not public
testing, there would not be an increased number of laboratories for consumers to
choose from. As a consequence, the cost competition benefit of having several
laboratories conducting public testing is not realized under this model. This
theory, however, would address the concern the plaintiffs have about Myriad
Genetics not sharing its database with the Breast Cancer Mutation Database.3"1
See supra note 276 and accompanying text.
s See supra note 281 and accompanying text.
See supra note 282 and accompanying text.
See supra note 278 and accompanying text.
301 See supra notes 29-31 and accompanying text.
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Under the OECD's model, informational databases should be shared and should
not be under the sole control of the licensor." 2 This model would be a good
starting point for change. It allows research on genes to continue with little or no
cost, thus protecting the consumer, while still allowing the company to reap the
rewards of its invention.
2. Increasing Transparengy. SACGHS suggests that patent holders be required
to make information about their licensing standards public.3 3 This would ensure
that those who wish to obtain a license to the patent holder's invention would not
be unduly burdened in finding needed information about the patent holder's
licensing standards. While Myriad Genetics claims that it did not wish to go after
researchers, researchers stopped their research in fear of possible infringement
lawsuits.3° Publicizing licensing information may help to increase the amount of
research that takes place. There are several ways to make this type of information
public. The biotechnology company could put the necessary licensing information
on their official website. Arguably researchers would likely begin their quest for
information at the company's website, making this a workable solution for both
parties. SACGHS suggested that the FDA and Medicare/Medicaid require
companies to make patent information available on the company's product. 3°5
This recommendation is also an effective way to communicate information to
researchers, while being a fairly simple fix for companies. Requiring that the
patent information be displayed on both a company's website as well as on the
product itself would be the best option. The only downside would be the actual
administration of the program. While many companies would likely voluntarily
display this information if requested, the FDA and Medicare/Medicaid may not
have the resources to oversee such a program. It would be possible, however, to
have a statutory penalty recoverable in a civil action for failure to provide the
required information. Any increase in the degree of transparency should be
encouraged. If adequate overhead for the program is not possible, then
companies should be requested to comply with these transparency guidelines on
a voluntary basis.
3. AdditionalStatutoy Changes. SACGHS also suggests limiting "patenting of
diagnostic tests that rely on an association of a particular genotype with a
disease/disorder."3 6 If that is not possible, then it suggests allowing patents only
with certain conditions and having limitations placed on their scope.3 7 Thus, the
302 See supra note 279 and accompanying text.
o See spra notes 262-64 and accompanying text.
304 See supra Part II.B.3.
30s See supra note 264 and accompanying text.
o See supra note 270 and accompanying text.
S ee sVpra note 270 and accompanying text.
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SACGHS provides two alternatives: if a strict prohibition of patents on these
particular genes is not feasible, SACGHS recommends severely limiting their
scope. These suggestions directly interfere with the USPTO's Utility Examination
Guidelines, however, which allows patenting of diagnostic tests and genes that
have a known purpose.3°8 Limiting the ability to patent genes and tests that are
directly related to known diseases would be a huge benefit for the public.
However, these suggestions leave the companies that founded the test or isolated
the gene without reward for their efforts and deprive them of the incentive to
pursue further solutions. If these suggestions are implemented, companies would
no longer be able to patent genes (and related tests) that have a known purpose.
Thus, this suggestion in conjunction with the currently nullified USPTO Utility
Examination Guidelines would lead to a near prohibition on the patenting of
genetic inventions. While the idea is a good one, these suggestions may lean too
far on the side of the public to survive passing through the legislature.
SACGHS alternatively suggests that if gene patents are once again granted,
there should be limits on infringement liability for medical professionals and
researchers. 3°9 Unlike earlier suggestions, which would make licenses available to
these researchers and medical professionals for reduced royalty fees, SACGHS
suggests a blanket waiver of liability for these professionals. This would allow
researchers to continue their research to the benefit of the public. Medical doctors
would also be able to perform these tests for their patients. This suggestion,
however, prevents the patent holder from reaping the financial benefits of its
discovery. But, if the suggestion only included research activities and reinstated
liability for medical professionals conducting their own testing, a better balance
would be struck between the needs of the company and the needs of the public.
Under this revised theory, the public would benefit from continued research, while
the patent holder would continue to be the sole commercial source of the test.
C. LESSONS LEARNED FROM THE EUROPEAN UNION'S DEALINGS WITH MYRIAD
Taking into consideration the acts of the European Patent Office, several ideas
for dealing with this international problem may be gleaned. The system that most
closely resembles the United States' patent process is that of the EPO. Much like
its United States counterpart prior to the Myriad decision, the EPO allows isolated
genes to be patented "even if identical to the natural element."3"' It also mirrors
the USPTO's stance on diagnostic tests, which have been held to be patentable
3 See supra Part II.c. 7.
' See supra note 271 and accompanying text.
310 See supra note 217 and accompanying text.
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under both regimes." The United States should utilize the EPO's opposition
procedure in the event that the Myriad decision is overturned on appeal. Through
the EPO's opposition process, individuals and organizations have the opportunity
to oppose a patent application even after it has been granted.312 When this process
was used by several organizations in Europe, the EPO was forced to reexamine
the patents it had granted to Myriad Genetics. The effect of this opposition was
the revocation and subsequent reinstatement of the patents in an amended
form.
3 14
To ensure that patents granted by the USPTO undergo a high level of scrutiny,
this type of public opposition procedure should be implemented if gene patents
are reinstated. The opposition procedure should allow any party, whether an
interested party or not, to submit a written challenge to the USPTO after a gene
patent has been granted. A statute of limitations should be put in place to ensure
a speedy resolution for all parties. After an opposition has been submitted, the
USPTO should investigate the claims made in the written opposition and make
a determination as to the product's patentability. Like the EPO's system, there
should be three possible outcomes: the patent could be upheld, voided, or upheld
in an amended form.
Had the United States implemented this type of opposition procedure earlier,
lawsuits, including the current controversy, could be wholly avoided. The
opposition to Myriad Genetics in Europe had many of the same concerns that the
plaintiffs raised in the current lawsuit. The EPO's opposition procedure is
successful because it addresses many concerns and narrows the patents without
costly litigation. In light of this small success, the United States should implement
a similar opposition procedure for patents on genetic materials. The procedure
appears to have worked in the European Union. While there may be an increased
cost of reevaluation on the front end, eliminating the need for court proceedings,
such as the current case, may be well worth the added expenditure. Additionally,
those who will be most affected by the patenting of a product, such as researchers
and patients, should have the ability to have their voices heard. Europe's
treatment of Myriad Genetics shows that a balance can be struck between the
financial interests of the patent holder and the interest of the public. While
Myriad Genetics got to keep its patents, the scope of these patents was
significantly narrowed from the originals. Had the United States used a similar
process when Myriad Genetics' patents were granted, it is likely that the broad
scope of the patents could have been sufficiently narrowed to protect the public
311 See supra notes 216-19 and accompanying text.
312 See sVpra notes 220-23 and accompanying text.
313 See supra notes 224-42 and accompanying text.
3 See supra notes 235-42 and accompanying text.
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interest. Additionally, the current case may not have been necessary, thus
improving judicial economy.
IV. CONCLUSION
The battle over whether genetic material should be patented is significant for
any person who has a loved one that may one day need to make a tough decision
about her health. Myriad Genetics has locked down the market for BRCA1 and
BRCA2 testing in the United States and abroad. This has stifled research,
restricted patents' access to care, increased costs, affected quality of care, and
interfered with patient rights.
Gene patents have become a hotbed for international debate. Several countries
have found that a full patent, like the United States once provided Myriad
Genetics, goes too far. In regions where opposition to patents is encouraged, such
as in the European Union, change has occurred: first with the revoking of such
patents, and then with their subsequent reinstatement in limited form.
The current patent process for genetic material is in a state of flux. Even with
the district court decision invalidating the BRCA patents, the unstable patent
process for gene patents is insufficient to protect the rights of patients in the
United States and around the world. The district court decision in the Myriad
Genetics' case is a good stepping-stone toward gene patent freedom. While the
decision has been both praised and criticized, everyone can agree that the fight
over gene patentability is far from being over. Though with the decision being
appealed, the future of gene patents remains uncertain.
At this juncture, it is prudent to look at all of the available options. While the
district court's decision may be upheld and gene patenting as we know it may be
a distant memory, there is a chance that the appellate court could side with Myriad
and reinstate their gene patents. Thus, this Note has outlined alternatives in light
of gene patents' uncertain future.
If gene patents are held to be valid once again, changes will have to be made
to the USPTO's Utility Examination Guidelines as they existed before the Myriad
decision and additional changes will have to be made by the legislature to ensure
that patients are not stripped of their right to make informed medical decisions.
A new system of opposition, based on the EPO's model, may help decrease
litigation costs while increasing awareness of gene patenting in the U.S. for
interested parties. The USPTO should be required to hear and address the
concerns of private companies, researchers, and others, in order to ensure that
only narrow gene patents are granted. If gene patents are reinstated, research will
once again be hampered because of the lack of a workaround for researchers.
Lastly, the United States should adopt a system of compulsory licensing of
genetics material to ensure wide dissemination of testing and research
2010]
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opportunities if the patents are upheld. This would show concern not only for the
patent, but also for the original patent holder's bottom line. Either way something
must be done. The appellate court will either have to uphold the invalidity of gene
patents, or the public and the legislature will have to step in and ensure that any
gene patents that are allowed are as widely licensed and as narrow in scope as
possible. Simply stated, the fight over gene patenting is far from over. The
plaintiffs in the Myriad case may have won the battle, but Myriad has vowed to
fight, and the war rages on.
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